Biotest GmbH & Co. KGaA (HMSE: BIO0)
Health Care · Biotechnology · DE
€33.40
+0.60% today · +11.3% 1Y
Biotest GmbH & Co. KGaA (HMSE: BIO0) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.54B and employs 2,495 people.
Over the last twelve months the share price has gained 11.3%, trading between 28.00 and 35.00.
Tweenvest scores Biotest GmbH & Co. KGaA across four factors: quality 56/100, value 55/100, growth 49/100, dividend 3/100. Its strongest factor is quality.
BIO0 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.54B
- Revenue (TTM)
- $761.89M
- P/E
- —
- EPS
- -1.79
- Dividend yield
- 0.12%
- Beta (5Y)
- —
- 52-week high
- €35.00
- 52-week low
- €28.00
- Avg volume (3M)
- —
- Shares outstanding
- 39.57M
- Employees
- 2,495
- Next earnings
- —
About Biotest GmbH & Co. KGaA
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
- ISIN
- DE000A41YE49
- Founded
- 1946
- Listed since
- Nov 17, 1998
- Exchange
- Hamburg Stock Exchange
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.